Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Accenture
US Department of Justice
Chubb
Boehringer Ingelheim
Deloitte
Cerilliant
AstraZeneca
Mallinckrodt

Generated: May 23, 2018

DrugPatentWatch Database Preview

VOTRIENT Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Votrient patents expire, and what generic alternatives are available?

Votrient is a drug marketed by Novartis Pharms Corp and is included in one NDA. There are three patents protecting this drug.

This drug has forty patent family members in twenty-five countries.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.
Summary for VOTRIENT
Drug patent expirations by year for VOTRIENT
Synonyms for VOTRIENT
33Y9ANM545
5-((4-((2,3-DIMETHYL-2H-INDAZOL-6-YL)(METHYL)AMINO)PYRIMIDIN-2-YL)AMINO)-2-METHYLBENZENESULFONAMIDE HYDROCHLORIDE
5-((4-((2,3-Dimethyl-2H-indazol-6-yl)methylamino)pyrimidin-2-yl)amino)-2-methylbenzenesulfonamide monohydrochloride
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]-2-pyrimidinyl}amino)-2-methylbenzenesulfonamide Hydrochloride
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride
5-({4-[(2,3-dimethylindazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzenesulfonamide hydrochloride
5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride
5-[[4-[(2,3-dimethyl-6-indazolyl)-methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide hydrochloride
5-[[4-[(2,3-dimethylindazol-6-yl)-methyl-amino]pyrimidin-2-yl]amino]-2-methyl-benzenesulfonamide hydrochloride
635702-64-6
786034 HYDROCHLORIDE
A834417
AC-24726
AK163181
AKOS015958593
AM20090655
AN-16933
Armala
ARMALA HYDROCHLORIDE
AX8294838
BCP9001052
Benzenesulfonamide, 5-((4-((2,3-dimethyl-2H-indazol-6-yl)methylamino)-2-pyrimidinyl)amino)-2-methyl-, monohydrochloride
Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1)
C21H23N7O2S.HCl
CHEBI:71217
CHEMBL1201733
CS-0126
D05380
DTXSID70212956
EX-A956
FT-0687642
GSK-786034
GW 786034
GW 786034 HYDROCHLORIDE
GW-786034B
GW786034B
GW786034GW786034
HY-12009
KB-79770
KS-000003E0
KS-1458
MFCD12546138
MLS004774147
MolPort-009-679-403
MQHIQUBXFFAOMK-UHFFFAOYSA-N
NSC-737754
NSC737754
Patorma
Pazopanib (Hydrochloride)
pazopanib HCl
Pazopanib HCl (GW786034 )
Pazopanib HCl (GW786034 HCl)
Pazopanib hydrochloride
Pazopanib hydrochloride (JAN/USAN)
Pazopanib hydrochloride [USAN:JAN]
pazopanib monohydrochloride
PB31655
S1035
SC-90768
SCHEMBL159487
SMR003500790
ST24048877
SYN1058A
UNII-33Y9ANM545
Votrient (TN)
VOTRIENT HYDROCHLORIDE
W-5532
X3177

US Patents and Regulatory Information for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Non-Orange Book US Patents for VOTRIENT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,858,626 Pyrimidineamines as angiogenesis modulators ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for VOTRIENT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
710 Luxembourg ➤ Try a Free Trial 91710, EXPIRES: 20250614
9 Finland ➤ Try a Free Trial
2010 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID
/2010 Austria ➤ Try a Free Trial PRODUCT NAME: PAZOPANIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES ODER SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/628/001 - EU/1/10/628/004 20100614
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Colorcon
Dow
Fuji
Boehringer Ingelheim
Queensland Health
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.